Cell Therapy News/Articles, page-81

Stem cell therapy, the next-gen way to treat diseases: expert

• Hindu

• Thiruvananthapuram

• Thu,26 Oct 2017

Summary: Stem cell, tissue engineering, and regenerative medicine were potential cash cows for Korea, he said. The Korean government, he said, was pushing commercialisation of stem cell for treatment of diseases. In stem cell technology, Japan and the U.S. were ranked top in academics, but when it came to commercialisation Korea had taken the lead. Knowing that it could not penetrate the multinational drug companies that controlled the sector, the country had decided to concentrate on the stem cell industry. This had occurred with industrialisation coupled with infrastructure building and science and technology development, he said.
India and China, in the near future, will emerge very strong in the medical sector, according to Gilson Khang of the Department of BIN Fusion Technology and Polymer Nano Science and Technology, Chonbuk National University, Korea. The population of over a billion people, the range of diseases, and level of quality of life in India were huge positives for the sector, he said. Mr. Khang, who delivered the Chandra P. Sharma Award Lecture on ‘Recent advances of the commercialisation for tissue engineered and regenerative products’ at the ongoing Sixth Asian Biomaterials Congress here, in a chat with The Hindu spoke about Korea’s focus on biotechnology, and stem cell technology, and its applications.
Mr , As Reported By Hindu.

According to the Newspaper,Khang is part of a panel that advises the Korean government. India, he said, could take a leaf from China’s book by pumping in research and development money on publication of scientific papers by academics. If India managed to attract its nationals settled in other countries by offering them better pay and other benefits, research and development would improve by leaps and bounds.


Life sciences in Korea
(Image: Australian delegation to BioKorea 2017)

AusBiotech has been working with Austrade Korea for several years to promote Australian biotechnology Korea, with particular focus on regenerative medicine, clinical trials, medical devices and diagnostics, biotechnology and pharmaceutical sectors. We participate in Korea’s flagship life science event, BioKorea.
AusBiotech has signed two Memorandums of Understanding (MoU) with Korea.
The first MoU was established with the Council for Advanced Regenerative Medicine (CARM). This agreement seeks to facilitate connections and spark innovation between the regenerative medicine industries in Korea and Australia.
The second MoU was signed with the Korea Health Industry Development Institute (KHIDI), a government-affiliated institution that leads the expansion of healthcare R&D investment and builds the competitiveness of Korea’s healthcare industry.
AusBiotech also has established strong connections with Korea’s Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC).
Find out more about Korea’s biotechnology sector in Korea’s sights set on Australia collaboration, an interview with Green Cross Holding’s Dr BG Rhee.